GPs to Receive Financial Incentives for Weight Loss Drug Prescribing Under New 2026-27 Contract

The Department of Health and Social Care has announced major changes to the GP contract for 2026-27 that place greater emphasis on obesity management, with GPs set to receive financial rewards for referring eligible patients to structured weight management programmes and prescribing weight loss medications where clinically appropriate.

The updated General Practice contract, backed by a total uplift of £485 million (a 3.6 per cent cash increase), includes two new obesity-related indicators within the Quality Outcomes Framework (QOF). These indicators will be supported by an additional 18 QOF points worth approximately £25 million, according to NHS England’s official announcement on 24 February 2026.

The new obesity indicators will reward GP practices that consistently identify and support adults living with obesity across England. Under the revised framework, practices will earn points by improving the recording of body mass index (BMI) data and offering appropriate weight management support to patients. This represents a significant shift from the previous Weight Management Enhanced Service, which is being retired as part of the contract changes.

The incentive scheme is intended to modernise obesity care delivery in primary care and align with updated guidance from the National Institute for Health and Care Excellence (NICE). By financial year 2026-27, GPs will have access to new funding streams specifically designated for identifying eligible patients and supporting their weight management journeys through both structured programmes and pharmacological interventions.

Weight loss medications such as tirzepatide (marketed as Mounjaro) fall within the medicines optimisation component of the new framework. These are injectable treatments that have demonstrated effectiveness in supporting weight loss in adults with obesity, particularly those with weight-related comorbidities such as type 2 diabetes. GPs will be incentivised to prescribe these medications where clinically appropriate for their patients, representing a more integrated approach to obesity management than previously available within the primary care setting.

However, medical experts have raised concerns about whether financial incentives alone will resolve the practical challenges surrounding weight loss drug availability and access. According to analysis by the British Medical Journal, experts warned that “the incentive will make no real difference to patients” without addressing underlying supply and rollout problems that have affected the wider NHS rollout of these medications.

The availability of weight loss jabs has been a significant challenge for NHS services, with supply constraints limiting the number of patients who can access treatment. Some experts have suggested that introducing GP-level incentives may create competition between general practices and hospital services for limited medication stock, potentially exacerbating access inequalities across different regions.

The obesity incentives form part of a wider overhaul of the GP contract designed to modernise primary care delivery. The 2026-27 contract also introduces a practice-level GP reimbursement scheme worth £292 million, aimed at enabling practices to recruit additional GPs or increase sessions from existing practitioners to support same-day urgent access.

Additional changes include strengthened vaccination indicators with new financial rewards for practices that demonstrate sustained improvement in childhood vaccination uptake, particularly in more deprived areas. The contract also updates diabetes and heart failure indicators to reflect current NICE best practice guidance.

The NHS Confederation and King’s Fund have welcomed the contract as evidence of the government’s commitment to strengthen the “front door” of the NHS and shift care out of hospital settings into community-based general practice. Over two years, general practice has now received an additional £1.7 billion in funding to support expanded capacity and services.

Obesity affects millions of adults across the UK and is a significant risk factor for serious health conditions including type 2 diabetes, cardiovascular disease, and certain cancers. The NHS currently provides various weight management services, including structured programmes and dietary support, though access varies significantly across different regions.

Weight loss medications represent an important tool within a comprehensive obesity management strategy, typically offered alongside lifestyle modifications including diet, physical activity, and behavioural support. GPs are well-positioned to identify eligible patients and monitor their progress, making primary care an appropriate setting for delivering these interventions.

The new contract framework aims to ensure more consistent identification and management of obesity across general practice, with the expectation that improved BMI recording and patient support will contribute to better long-term health outcomes for patients living with obesity and related conditions.

Key Takeaways

• GPs will receive £25 million in financial incentives through the Quality Outcomes Framework to identify patients with obesity and offer weight management support, including prescription of weight loss medications such as Mounjaro
• The updated contract introduces two new obesity-related indicators and retires the previous Weight Management Enhanced Service, reflecting alignment with current NICE guidance
• Medical experts have flagged concerns that incentives alone will not resolve underlying supply and access challenges that have affected wider NHS rollout of weight loss jabs

What This Means for Kent Residents

For residents across Kent and Medway, the updated GP contract offers potential benefits in terms of improved obesity identification and management within general practice settings. Kent and Medway NHS Trust, along with local integrated care boards, will be responsible for commissioning and supporting the implementation of these new indicators within primary care.

Patients with obesity, particularly those with related health conditions, should expect their GP to conduct more routine BMI assessments and discuss available weight management options. However, patients should be aware that access to weight loss medications through primary care will depend on clinical eligibility criteria and local prescribing protocols. Those interested in weight management support should speak with their GP practice about what services are available locally, including both structured weight loss programmes and medication-based interventions where appropriate. GP practices across Kent will be required to maintain up-to-date recording of patient BMI data as part of the new contract requirements.